Publications by authors named "R M Giusti"
Background: Patients with head and neck cancer (HNC) bear a significant load, due to both disease-related symptoms and to toxicities associated with treatments. Evaluating quality of life (QoL) is crucial to gauge the physical and psychological impact on these patients. Our primary aim was to assess whether QoL has been incorporated as an endpoint in phase II and III clinical trials for HNC patients in the last 15 years.
View Article and Find Full Text PDFArticle Synopsis
- Small-Cell Lung Cancer (SCLC) makes up 15% of lung cancer cases and is often aggressive, leading to severe symptoms even before metastasis.
- There is a lack of consistency in how palliative care is integrated with cancer treatments, which can leave patients with unmet needs.
- A survey by 13 experts from Lazio found significant variation in the management of SCLC, prompting the group to develop practical recommendations to standardize patient care in the region.
: Single-agent immune checkpoint inhibitor (IO) therapy is the standard for non-oncogene-addicted advanced non-small cell lung cancer (aNSCLC) with PD-L1 tumor proportion score ≥ 50%. Smoking-induced harm generates high tumor mutation burden (H-TMB) in smoking patients (S-pts), while never-smoking patients (NS-pts) typically have low TMB (L-TMB) and are unresponsive to IO. However, the molecular characterization of NS-pts with H-TMB remains unclear.
View Article and Find Full Text PDFBackground: Medical cannabis (MC) has gained traction in oncology for managing cancer-related symptoms, but its integration faces challenges due to limited evidence, inconsistent guidelines, and varied legal frameworks.
Methods: The TASMAN study aimed to assess the knowledge, attitudes, and practices of oncologists and palliative care providers globally regarding MC use in cancer care. A survey of healthcare providers from diverse regions and income levels was conducted.